Mumbai - Wockhardt Hospitals, Mira Road recently managed a rare and challenging cardiac case where “silent” venous occlusion ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Medanta Medicity doctors said the case highlights the expanding role of image-guided interventions in managing high-flow AVMs ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns.

"Okami secures $45m to advance clinical programmes for vascular disease" was originally created and published by Medical Device Network, a GlobalData owned brand.